tirzepatide diabetes trial for diabetes: on track to SURPASS current therapy EASD 2023: meta-analysis shows tirzepatide

95% CI, 0.8-0.94 vs

After one year, 42% of adults on Zepbound and 50% of adults on Zepbound with PAP therapy experienced remission or mild, non-symptomatic OSA, compared to 16% and 14% on placebo, respectively

Super responsive

Risk factors include renal impairment, concomitant use of certain drugs, age 65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, and hepatic impairment

Sterility : Since it is administered via IV, it must be produced and packaged in a sterile environment to prevent infections

PLoS ONE 19(5):e0302015 AbdelAziz EY, Tadros MG, Menze ET (2021) The effect of metformin on indomethacin-induced gastric ulcer: involvement of nitric oxide/Rho kinase pathway